

Managing metastatic renal cell carcinoma- challenges, pitfalls, and outcomes in the real world

Karnam Ashok Kumar,
Gundeti Sadashivudu,
K. V. Krishnamani,
Vijay Gandhi Linga,
Lakshmi Srinivas Maddali,
Raghunadha Rao Digumarti

Department of Medical Oncology,
Nizam's Institute of Medical
Sciences, Hyderabad, Telangana,
India

Address for correspondence:

Dr. Karnam Ashok Kumar,
Department of Medical Oncology,
Nizam's Institute of Medical
Sciences, Hyderabad - 500 082,
Telangana, India.
E-mail: ashokpillai005@gmail.com

INTRODUCTION

Renal cell carcinoma (RCC) is the most common cancer of the kidney, accounting for 85% of renal tumors.^[1] According to the American Cancer Society estimates, RCC is the seventh most common cancer and is the tenth leading cause for cancer-specific deaths.

Data from India regarding the incidence and mortality of RCC are lacking, but RCC does not figure in the top ten cancers-incidence and mortality wise.

Up to 30% patients with RCC present with metastatic disease^[2,3] and recurrence develops in approximately 40% of patients treated for a localized tumor.^[2,4] Treatment for localized disease is surgery whereas metastatic disease is treated with systemic therapy. There has been a paradigm shift in the management of metastatic RCC (mRCC) with the emergence of tyrosine-kinase inhibitors (TKIs) and monoclonal antibodies as systemic therapy.

Despite these advancements, survival has largely remained unchanged, and prognosis for Stage IV disease continues to remain poor.

ABSTRACT

Introduction: Renal cell carcinoma (RCC) is the most common cancer of the kidney accounting for 85% of renal tumors. Metastatic RCC (mRCC) had a poor prognosis and with the introduction of tyrosine-kinase inhibitors, such as sunitinib, pazopanib the outcomes improved. There is only one study reported from India on the use of sunitinib in mRCC. We present our analysis of mRCC and use of sunitinib at our institute over 5 years. **Materials and Methods:** All patients with mRCC receiving sunitinib were analyzed with respect to patient characteristics, response, toxicity, and outcomes. **Results:** A total of 108 patients were seen during the study period. The male to female ratio was 9.8:1. The median age of patients at presentation was 58 years (range: 15–80 years). Of the 108 patients, 68.51% had metastatic disease at initial presentation. The most common sites of metastases were lung followed by bone. Of the 97 patients eligible for sunitinib, only 76 received at least one cycle of sunitinib, out of which only 48 received further cycles (range: 2–36). The median progression-free survival (PFS) and overall survival (OS) in our patients were 10.2 and 28.2 months, respectively. The most common adverse effect noticed in our population was mucositis followed by hand-foot syndrome. **Conclusion:** Sunitinib is an option for the treatment of mRCC and shows a good PFS in Indian patients. Median OS and PFS in this study are similar to other reported studies despite the presence of poor risk factors in the patient population. The pitfall in this study is significant attrition due to poor compliance to treatment and follow-up, which is a major factor in the clinic thereby compromising outcomes.

Key words: *Metastatic renal cell carcinoma, outcomes, sunitinib*

MATERIALS AND METHODS

All patients with a histopathological diagnosis of RCC in tertiary care university hospital in South India between January 2009 and December 2013, and a minimum follow-up of 12 months were included in this analysis. All patients with metastatic disease received sunitinib as the first line therapy, irrespective of histology and risk score. Sunitinib was provided free of cost through a patient assistance program. Analysis consisted of demographic profile, sites of metastases, starting dose of sunitinib, response, toxicity profile, progression-free survival (PFS), and overall survival (OS). The presence of comorbidities especially smoking, obesity, and chronic renal failure (chronic kidney disease [CKD]) were noted. Patients were started on sunitinib at a dose of 37.5 mg or 50 mg once a day based on Eastern Cooperative Oncology Group Performance Score. The schedules followed were 4 weeks on and 2 weeks off drug, or a

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Kumar KA, Sadashivudu G, Krishnamani KV, Linga VG, Maddali LS, Digumarti RR. Managing metastatic renal cell carcinoma-challenges, pitfalls, and outcomes in the real world. Indian J Med Paediatr Oncol 2016;37:260-4.

Access this article online

Quick Response Code:



Website:
www.ijmpo.org

DOI:
10.4103/0971-5851.195738

2-week on 1-week off schedule. Response assessment was based on clinical and radiological criteria. Response evaluation was done using response evaluation criteria in solid tumors version (RECIST) criteria. Response was classified as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). Clinical progression and cancer-related deaths were considered as progression. Response evaluation was done after 2–4 cycles of sunitinib. Progression-free survival was calculated as the time between the start of therapy and the date of progression or death from any cause. OS was calculated as the time between start of therapy and the date of death due to any cause. Toxicity profile was calculated according to the common terminology criteria for adverse effects version 4.0. Graphpad prism 6 was used for statistical analysis. Survival was calculated using Kaplan–Meier method.

RESULTS

A total of 108 patients were seen during the study period. Ninety-eight patients (90.74%) were male. The male to female ratio was 9.8:1. The median age of patients at presentation was 58 years (range: 15–80 years). Risk factors such as smoking, obesity, and CKD were noted in 64 (59.25%), 36 (33.33%), and 9 (8.33%), respectively. Bilateral RCC was seen in only one patient. The most common presentations were hematuria in 64 patients (59.25%) followed by loin pain in 62 patients (57.4%). The clinical triad of hematuria, loin pain, and fever was present in 23 patients (21%) only [Table 1].

In this study, most of the patients were included in intermediate and poor risk except 3.7% of the study group, which was depicted in Table 2.

The histopathological variants and sites of metastases are mentioned in Tables 3 and 4, respectively.

Clear cell carcinoma was the most common histologic variant, reported in 84.25% of patients.

Of the 108 patients, 34 (31.48%) had localized disease and the remaining 74 (68.51%) had metastatic disease at initial presentation [Table 5]. The most common sites of metastases were lung in 47 patients (48.45%), followed by bone in 23 patients (23.71%).

Surgery was performed in sixty patients (55.5%). Of the 60 patients, 34 (56.66%) had radical nephrectomy. Of the 34 patients who had radical nephrectomy for localized disease, 23 (67.64%) became metastatic over a median period of 13.65 months. Palliative nephrectomy was done in 26 patients with persistent hematuria or intractable pain in which 21 (80.76%) patients had disease progression.

There was a significant attrition observed in this study. The number of patients eligible for sunitinib at first visit

was 97 (89.98%). Out of them, 74 (76.28%) patients had metastasis upfront and 23 (13.70%) patients developed metastasis later on during the course of follow-up. Of the 74 patients who had metastasis at presentation, 21 (28.37%) patients did not return after the first visit and a further 28 were lost to follow-up after one cycle.

Table 1: Demographic and clinical characteristics of patients with renal cell carcinoma

Parameter	Result (%)
Median age (range)	58 years (15–80)
Sex (male:female)	98:10; 90.74:9.25
Smoking	64 (59.25)
Chronic kidney disease	9 (8.33)
Obesity	36 (33.33)
Hematuria	64 (59.25)
Loin pain	62 (57.40)
Flank mass	24 (22.22)
Fever	23 (21.29)
Weight loss	58 (53.70)

Table 2: Heng risk stratification

Risk	n (%)
Favorable (%)	4 (3.7)
Intermediate (%)	42 (38.88)
Poor (%)	62 (57.40)

Table 3: Histopathology

Histopathology	n (%)
Clear cell carcinoma	91 (84.25)
Papillary carcinoma 1 and 2	11 (10.18)
Sarcomatoid	6 (5.55)

Table 4: Sites of metastasis

Sites of metastasis	n (%)
Lung	47 (48.45)
Bones	23 (23.71)
Liver	13 (13.40)
Soft tissues	7 (7.21)
Skin	3 (3.09)
Central nervous system	4 (4.12)
No metastasis	11 (10.1)

Table 5: Targeted therapy

Patients	n (%)	Patients lost to follow-up
Number of patients eligible for sunitinib	97 (89.98)	
Upfront metastatic	74 (76.28)	21 (28.37%) lost follow-up after initial visit
Metastatic during follow-up	23 (13.70)	
Number of patients on sunitinib	76 (78.35)	28 (36.84%) lost follow-up after one cycle

Seventy-six (78.35%) patients received sunitinib at a dose of 50 mg/day or 37.5 mg/day based on PS (PS 0-1-50 mg and PS \geq 2-37.5 mg).

In these 76 patients who are eligible for sunitinib, 28 (36.84%) received only one cycle and lost for follow-up may be due to toxicity or due to disease progression.

The remaining 48 (49.98%) patients had received at least two cycles of sunitinib (range: 2–36). Of the 48 patients, 40 (83.33%) were started on 4 weeks on and 2 weeks off schedule and 8 were started on 2 weeks on 1 week off schedule. The median number of cycles received was five. The median dose of sunitinib received was 50 mg/day.

The adverse effect profile of the patients is shown in Table 6. The most common adverse effect noticed in our population was mucositis in 31 patients (18.67%) followed by hand-foot syndrome in 25 patients (15.06%).

The treatment response is measured using RECIST criteria and response achieved is shown in Table 7. After disease progression, only seven patients received second-line treatment, three received sorafenib, and four received everolimus.

DISCUSSION

RCC accounts for 85% of renal tumors. Cigarette smoking doubles the likelihood of renal-cell carcinoma and contributes to as many as one-third of all cases.^[5,6] Obesity is also a risk factor, particularly in women, in whom there is a linear relation between increasing body weight and the increased risk of renal-cell carcinoma.^[7,8] Kidney tumors usually are unilateral but may be bilateral in 2%–4% of cases.^[9]

Up to 30% patients with RCC present with metastatic disease. Lung metastases are the most common sites of distant relapse, occurring in 50%–60% of patients.^[10,11] The median time before a relapse after nephrectomy is 15–18 months, and 85% of relapses occur within 3 years.^[10,11] Hormonal and chemotherapeutic agents have little or no effect against renal-cell carcinoma.^[12]

Standard therapy for mRCC involves treatment with TKI. Approved agents for first-line use in clear cell RCC include pazopanib, sunitinib, and bevacizumab and interferon combination according to ESMO and NCCN guidelines. In nonclear cell variants, m- TOR inhibitor like temsirolimus is used as the first line.

This study was carried out in mRCC, and the objectives were to evaluate the demographic profile, sunitinib, adverse effects, response rates, and survival. There is only one study examining the use of sunitinib from India.

The data of these studies are summarized in Table 8.

The median age of presentation in our study is 58 years. This is lower than other studies by Motzer *et al.* and Yuasa *et al.*

suggesting that the age of onset of RCC might be earlier in our population. Similar to other studies the males were more than females in our study, however, the ratio of male to female was much higher (9.8:1) when compared to those studies.^[13-16] The percentage of patients who were eligible for sunitinib in our study (i.e. with a performance score of 0–1) was lower when compared to other studies. Delay in diagnosis, poor follow-up after radical nephrectomy, compliance, lack of awareness, and lack of cancer care centers might be reasons for a low-performance score at presentation.

The percentage of patients who were anemic (low Hb-which is a risk stratification parameter) at presentation was more in our study when compared to other studies; this may be because of poor nutrition and low-socioeconomic status.

Our patients had fewer better prognostic factors when compared to previous studies. The number of patients who had calcium <10 g/L was more in our study when compared with Yuasa *et al.*^[14] The percentage of patients with LDH more than 1.5 times the upper limit of normal was 64.81%. It was less when compared with 80.95% in Yuasa *et al.*^[13] In our study, 68.42% of patients presented earlier with metastatic disease, i.e., <1 year when compared to 47.61% in Yuasa *et al.* study.^[13]

The most common histology seen in our population was clear cell carcinoma seen in 84.25% which was similar to other studies. The most common site of metastasis was lung followed by bone and liver metastasis which was similar to other studies and the least common site of metastasis was the brain.

Table 6: Adverse effects

Adverse effect	n (%)	Grade 3 and 4 (%)
Hypothyroidism	23 (13.85)	8.69
Hand-foot syndrome	25 (15.06)	4.8
Diarrhea	9 (5.42)	11.11
Hypertension	24 (14.45)	33.33
Mucositis	31 (18.67)	80.64
Fatigue	24 (14.45)	70.83
Leucopenia	16 (9.63)	18.75
Thrombocytopenia	14 (8.43)	14.28
Total events	166 (100)	

Table 7: Efficacy

Efficacy	n (%)
Complete response	0
Partial response	22 (45.83)
Stable disease	20 (41.66)
Progressive disease	6 (12.5)
Disease control rate	42 (87.49)
Progression-free survival (median in months)	10.2
Overall survival (median in months)	28.2
Death rate	37/76 (48.68)

Only 55.55% of our patients underwent nephrectomy when compared to 77.77% in Yuasa *et al.*^[13] and 90.2% in Kim *et al.*^[15] The clinical efficacy rate (CR + PR + SD) was 86% in our study when it was 81% in Yuasa *et al.*^[13] and 76% in Krishna *et al.*^[13]

In our study, 12.5% of patients had PD after the use of sunitinib.

The median values of PFS [Figure 1] and OS [Figure 2] in our patients were similar to other previous studies. The median PFS was 10.2 months in our study, 11.4 months in

Krishna *et al.*,^[13] 9.3 months in Yuasa *et al.*,^[13] 8.2 months in Kim *et al.*,^[15] and 11.0 months in Motzer *et al.*^[16]

The median OS in our patients was similar to previous reports. The median OS in our patients was 28.2 months when compared to 22.6 months in Krishna *et al.*,^[14] 32.2 months in Yuasa *et al.*^[13] and 23.1 months in Kim *et al.*^[15]

Despite our patients faring worse in nutritional parameters such as hemoglobin, body mass index, serum calcium, and PS, the median OS and PFS are similar to other studies




Figure 1: Kaplan–Meier estimates of progression-free survival (PFS)




Figure 2: Kaplan–Meier estimates of overall survival (OS)

Table 8: Comparison of our study with previous studies

	Present study	Krishna <i>et al.</i> ^[13]	Yuasa <i>et al.</i> ^[14]	Kim <i>et al.</i> ^[15]	Motzer <i>et al.</i> ^[16]
Age (years)	58	55	62	57	62
Sex					
Male	98	51	50	106	267
Female	10	8	13	26	108
ECOG PS, %					
0-1	71.2	84.7	82.5	87.8	
Hemoglobin (g/dL), %					
Anemia	65.7		58.7		219
Serum calcium (mg/dL), %					
>10	12.03		88.88		46
Serum LDH (IU/L), %					
>1.5 times UL	64.81		80.95		
Absolute neutrophil count, %					
≥ULN	76.85		87.30		34
Platelet count, %					
≥ULN	29.62		93.65		
Time from diagnosis to treatment, %					
>1 year	31.57		52.38		
Nephrectomy done	55.55		77.77	90.2	340
Lung metastasis present	43.51	35	68.25	78	292
Efficacy					
PFS	10.2	11.4	9.3	8.2	11
OS	28.2	22.6	32.2	23.1	

ECOG – Eastern Cooperative Oncology Group; PS – Performance status; LDH – Lactate dehydrogenase; PFS – Progression-free survival; OS – Overall survival; ULN – Upper limit of normal; UL – Upper limit

probably hinting toward better disease biology among our patients which needs further validation in large-scale studies.

A few limitations of this study are its retrospective nature, small sample size, and high levels of attrition.

CONCLUSION

Median values of OS and PFS in this study are similar to other reported studies despite the presence of poor risk factors in the patient population. The pitfall in this study is significant attrition due to poor compliance to treatment and follow-up, which is a major factor in the clinic, limiting optimal, and standard treatment, thereby compromising outcomes. This poor follow-up may be due to toxicity, major concern which needs tailoring the dose of therapy, adequate counseling, and careful follow-up which are essential for better outcomes.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005;55:74-108.
2. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. *World J Urol* 2005;23:202-12.
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. *N Engl J Med* 1996;335:865-75.
4. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. *Urol Clin North Am* 2003;30:843-52.
5. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, *et al.* Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2006;24:16-24.
6. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, *et al.* Sunitinib in patients with metastatic renal cell carcinoma. *JAMA* 2006;295:2516-24.
7. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, *et al.* Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. *J Clin Oncol* 2000;18:2972-80.
8. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. *Mol Cancer Ther* 2003;2:471-8.
9. Moertel CG, Dockerty MB, Baggenstoss AH. Multiple primary malignant neoplasms. I. Introduction and presentation of data. *Cancer* 1961;14:221-30.
10. Sandock DS, Seftel AD, Resnick MI. A new protocol for the follow up of renal cell carcinoma based on pathological stage. *J Urol* 1995;154:28-31.
11. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy. *J Clin Oncol* 1994;12:206-12.
12. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. *Semin Oncol* 1995;22:42-60.
13. Krishna VM, Noronha V, Prabhaskar K, Joshi A, Patil V, Bhosale B, *et al.* Sunitinib in metastatic renal cell carcinoma: A single-center experience. *Indian J Cancer* 2013;50:268-73.
14. Yuasa T, Tsuchiya N, Urakami S, Horikawa Y, Narita S, Inoue T, *et al.* Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib. *BJU Int* 2012;109:1349-54.
15. Kim HS, Hong MH, Kim K, Shin SJ, Ahn JB, Jeung HC, *et al.* Sunitinib for Asian patients with advanced renal cell carcinoma: A comparable efficacy with different toxicity profiles. *Oncology* 2011;80:395-405.
16. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, *et al.* Sunitinib versus interferon Alfa in metastatic renal-cell carcinoma. *N Engl J Med* 2007;356:115-24.